CST3 and acute kidney injury: The breakdown of absolute excess in cystatin C–defined AKI in the rosuvastatin group compared to the placebo group was the following: stage 1 (2.5 ± 1.1%); stage 2 (1.3 ± 0.4%); and stage 3 (0.3 ± 0.4%).